Menu
Share this

PPD Recognized for Excellence in Clinical Trial Monitoring

Clinical research associates earn top honors at PharmaTimes’ industry competition

18 Nov. 2013

RSS

WILMINGTON, N.C. (November 18, 2013) – Pharmaceutical Product Development, LLC (PPD) today announced that company clinical research associates (CRAs) earned recognition as top CRAs at the annual PharmaTimes U.S. Clinical Researcher of the Year competition.

Rebecca York, a senior CRA based in Austin, Texas, won the gold award in the New Clinical Research Associate category, which recognizes researchers with up to four years of experience. She was among 64 finalists across multiple categories to face a series of competency-based challenges and was rewarded for her knowledge, skills and expertise by a panel of biopharmaceutical industry judges. PPD’s Kelly Little, a CRA based in San Diego, won the bronze award in the new CRA category.

“Rebecca and Kelly exemplify the high caliber of CRAs that PPD deploys on client studies,” said Donna Hellsten, PPD vice president of clinical development in North America. “They embody the expertise, dedication and commitment to excellence that PPD clients expect. Our skilled CRAs ensure PPD delivers performance, quality and value to study sites around the world.”

PPD prepares CRAs to monitor clinical trials with its industry-leading clinical foundation program that utilizes PPD® 3D, an award-winning, virtual learning environment for collaborative, instructor-led and self-directed training. Online, participants simulate clinical monitoring activities, including protocol review, regulatory document review, informed consent monitoring, investigational product accountability and documenting monitoring tasks and communication with the trial site.

The PharmaTimes competition offers clinical researchers the opportunity to benchmark their skills against industry peers. The challenge has three phases, including a preliminary multiple-choice exam followed by essay questions for those advancing to the second round. For the finals, CRAs are presented a real-world scenario and given one hour to prepare a response for a panel of judges. Winners are determined by their answers to follow-up questions that assess their knowledge, innovation, creativity and ability to collaborate.

“It was an honor to receive this award on behalf of all CRAs at PPD,” York said. “PPD’s learning and development programs prepared me for this rigorous competition, and this recognition underscores PPD’s leadership in training and commitment to providing the best support for clients’ clinical research programs.”

PharmaTimes established the Clinical Researcher of the Year competition, with events held in the United States and London each year, to recognize and encourage outstanding clinical research professionals. At PharmaTimes’ London competitions, a PPD CRA was named the 2013 Clinical Research Associate of the Year, and a team of PPD researchers was honored as the 2012 Clinical Team of the Year.

About PPD
PPD is a leading global contract research organization providing drug discovery, development, lifecycle management and laboratory services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and more than 13,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments. 

Contacts

Media:
Lee Kennedy
+1 919 456 5350
lee.kennedy@ppdi.com

Investors:
Luke Heagle
+1 910 558 7585
luke.heagle@ppdi.com

Except for historical information, all of the statements, expectations and assumptions, including statements, expectations and assumptions about PPD’s PharmaTimes awards and PPD’s training programs, contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based and could cause actual results to differ materially from the forward-looking statements. Other important factors that could cause future results to differ materially include the following: the ability to attract, integrate, retain and train key personnel; competition in the outsourcing industry; rapid technological advances that make our services or capabilities less competitive; compliance with drug development regulations; changes in the regulation of the drug development process; risks associated with and dependence on strategic relationships; PPD’s ability to win new business; overall global economic conditions; economic conditions, research and development spending, and outsourcing trends in the pharmaceutical, biotechnology and government-sponsored research sectors; consolidation in the pharmaceutical and biotechnology industries; loss, delay or modification of large contracts; higher-than-expected cancellation rates; the rate of conversion of backlog into revenue; actual operating performance; risks associated with acquisitions and investments; and the ability to control SG&A spending. PPD assumes no obligation and expressly disclaims any duty to update these forward-looking statements in the future, except as required by applicable law. These forward-looking statements should not be relied upon as representing PPD’s estimates or views as of any date subsequent to the date hereof.

Media Contacts:

Randy Buckwalter Senior Manager, Corporate Communications
PPD
Tel: +1 919 456 4425

Elizabeth Humphrey Corporate Communications Manager
PPD
Tel: +1 910 558 6096

Contact Legal Notices Modern Slavery Transparency Statement Privacy Policy

© 2017 Pharmaceutical Product Development, LLC. All rights reserved.